THE PINK VIAL CO.

Research Peptide GLP-2 (TR)
Research Product

GLP-2 (TR)

Research GradeDocumentation Ready
Research Grade · Third-Party Verified
CAS: DA-78491 C225H348N48O68 ≥ 99% Pure
Price range: $49.99 through $119.99
For Research Use Only. Not intended for human or veterinary use. Read our full Research Disclaimer.
Fast processingOrders prepared promptly
Third-party documentationLot-specific COA when published
Research gradeLaboratory-use presentation
Category:

Description

About This Research Preparation

GLP-2 TIRZ is supplied as a combined lyophilized research preparation pairing a GLP-2 (glucagon-like peptide-2) research peptide with tirzepatide, a synthetic dual incretin-class peptide that engages both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor pathways. The listed molecular formula, C225H348N48O68 (average mass approximately 4814 g/mol), corresponds to the tirzepatide component and reflects the fatty-acid-modified backbone characteristic of long-acting incretin-mimetic research peptides. This material is offered strictly For Research Use Only and is not intended for human or veterinary use; supply is limited to laboratory research, analytical assay development, and investigative procedures. It is not a drug, supplement, or food.

Additional information

Select Strength

15mg, 30mg, 60mg

Scientific / technical description

Research Context
The two peptide classes represented in this preparation have each been the subject of separate bodies of preclinical and in-vitro literature. GLP-2 has been studied in cell-culture and animal models for its role in intestinal epithelial receptor signaling mediated through the GLP-2 receptor. Tirzepatide has been characterized in receptor-binding, cyclic-AMP signaling, and rodent model studies as a unimolecular agonist active at both GIP and GLP-1 receptors. Combining the two in a single research preparation is of interest to investigators studying gut-peptide receptor crosstalk, comparative incretin signaling, and multi-receptor pharmacology in controlled in-vitro systems. All such work to date is preliminary, ongoing, and mechanistic in nature; this content is educational and does not constitute medical advice, and no human or clinical conclusions should be drawn from it.

Reported Areas of Preclinical Investigation
Receptor-binding and functional agonism assays at GIP, GLP-1, and GLP-2 receptors in transfected cell lines
In-vitro cyclic-AMP and downstream signaling readouts used to characterize incretin-class peptides
Rodent and cell-model studies of intestinal epithelial and receptor signaling pathways
Comparative stability and receptor-selectivity profiling versus native GLP-1, GIP, and GLP-2 sequences
Analytical method development, reference-standard qualification, and assay validation workflows
Analytical Characterization
Each research lot is characterized to a purity specification of at least 99 percent and released against a certificate of analysis (COA). Identity and purity are established using orthogonal analytical methods appropriate to synthetic peptides of this size.

Purity: at least 99 percent as determined by reversed-phase high-performance liquid chromatography (RP-HPLC), typically with UV detection to quantify the main peak against process-related impurities
Identity / mass confirmation: mass spectrometry (ESI-MS or MALDI-TOF) to confirm the observed molecular mass against the theoretical value of the tirzepatide component (formula C225H348N48O68, ~4814 g/mol)
Reference identifier: CAS/catalog code DA-78491 for lot traceability
Documentation: lot-specific COA reporting chromatographic purity, mass-spec identity, and appearance for each preparation
Supplementary tests that may accompany a peptide COA include water/residual-solvent content, net peptide content, and counter-ion determination

Composition

The preparation contains the following peptide components:

GLP-2 research peptide
Tirzepatide
Tirzepatide Analytical Information
Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
Approximate average molecular mass: 4,814 g/mol
Physical form: Lyophilized
Purity specification: ≥99%
Reference/catalog identifier: DA-78491

The molecular formula and approximate molecular mass listed above correspond to the tirzepatide component and do not necessarily represent the molecular formula or molecular mass of the complete combined preparation.

Research-use status

For lawful laboratory, analytical, academic, and scientific research only. Not for human or veterinary use.

Important Research Notice

This product is sold strictly for research and laboratory use. It is not intended for human or veterinary administration, diagnosis, treatment, cure, mitigation, prevention of disease, or incorporation into products intended for human or animal consumption.

Purchasers are responsible for lawful acquisition, storage, handling, transportation, and use, including compliance with applicable federal, state, local, institutional, and laboratory requirements.

Frequently Asked Questions

What is this product?

This listing is for a research material offered for lawful laboratory and analytical use only. Review the product-specific technical information and documentation above before purchasing.

How is product documentation provided?

Where available, a lot-specific Certificate of Analysis is linked directly from this product page. Documentation is for research traceability and does not constitute FDA approval or authorization for human or veterinary use.

Is this product intended for human or veterinary use?

No. Products sold by The Pink Vial Co. are intended strictly for research, laboratory, analytical, academic, or scientific purposes and are not intended for administration to humans or animals.

Where can I find the research disclaimer?

The full site research disclaimer is provided in the footer and on the dedicated Research Disclaimer page.

Related products